文献速递浆细胞疾病

贝兰他单抗莫福汀所致眼部毒性对晚期多发性骨髓瘤患者结局的影响

Impact of belantamab mafodotin-induced ocular toxicity on outcomes of patients with advanced multiple myeloma.
PubMed 文献 · Br J Haematol · 2022-06-13

该研究纳入38例在临床试验外连续接受贝兰他单抗莫福汀(BLMF)治疗的晚期多发性骨髓瘤患者,75%出现眼部毒性,69%发生角膜病变;因眼部毒性永久停药(14%)或减量(11%)者中,70%在BLMF中断或减量后中位3个月内出现疾病进展(95%CI:0.2-未达到)。作者认为眼部毒性是常规临床实践中持续使用BLMF的主要障碍。

要点

  • 38例连续接受BLMF治疗的患者中,75%出现眼部毒性,69%发生角膜病变。
  • 因眼部毒性永久停药者占14%,减量者占11%。
  • 停药或减量者中70%在中位3个月内出现MM进展(95%CI:0.2-未达到)。

核心结论

  • 眼部毒性是常规临床实践中持续使用BLMF的主要障碍,需开发有效预防和减轻眼部毒性的措施以充分发挥该药潜力。

研究设计与样本

  • 研究为队列研究,纳入38例在临床试验外连续接受BLMF治疗的晚期多发性骨髓瘤患者。

主要发现

  • 75%的患者出现眼部毒性,69%发生角膜病变。
  • 因眼部毒性相关永久停药者占14%,减量者占11%。
  • 在因眼部毒性永久停药或减量的患者中,70%于BLMF中断或减量后中位3个月内出现MM进展(95%CI:0.2-未达到)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Belantamab mafodotin (BLMF) is a B-cell maturation antigen-directed antibody-drug conjugate, recently approved for advanced multiple myeloma (MM). The impact of BLMF-induced ocular toxicity on patient outcomes is unknown. We studied a cohort of 38 consecutively seen patients treated with BLMF outside of trials. Of those, 75% experienced ocular toxicity, with 69% developing keratopathy. Among patients requiring ocular toxicity-related permanent BLMF discontinuation (14%) or dose reduction (11%), 70% had progression of MM within a median of 3 months (95% confidence interval: 0.2-not reached) following BLMF interruption or dose reduction. Ocular toxicity is a major deterrent to the continuous use of BLMF in routine clinical practice. Measures to successfully prevent and mitigate ocular toxicity should be developed to achieve the full potential of this agent.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Abeykoon JP, Vaxman J, Patel SV, et al. Impact of belantamab mafodotin-induced ocular toxicity on outcomes of patients with advanced multiple myeloma. Br J Haematol. 2022. PMID: 35694818. doi:10.1111/bjh.18298

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。